ESCMID免疫功能受损宿主感染研究组(ESGICH)关于靶向与生物治疗安全性的共识文件:感染病学视角(靶向淋巴或髓系细胞表面抗原的药物[II]:CD22、CD30、CD33、CD38、CD40、SLAMF-7与CCR4)
本综述为ESGICH共识文件的一部分,从感染病学角度评估靶向CD22、CD30、CD33、CD38、CD40、SLAMF-7和CCR4药物的感染风险谱,并给出预防建议。CD30靶向药推荐抗肺孢子菌预防和CMV监测;CD38靶向药增加VZV感染风险;CD40靶向药相关机会性感染需预防策略;CCR4靶向药推荐抗肺孢子菌和抗疱疹病毒预防及慢性HBV筛查。
要点
- CD30靶向药(维布妥昔单抗)推荐抗肺孢子菌预防和CMV监测。
- CD38靶向药(达雷妥尤单抗)增加水痘-带状疱疹病毒感染风险。
- CCR4靶向药(莫格利珠单抗)推荐抗肺孢子菌和抗疱疹病毒预防及慢性HBV筛查。
核心结论
- 应制定具体管理策略以降低所评估药物相关感染并发症的风险和/或严重程度。
研究设计与样本
- ESCMID免疫功能受损宿主感染研究组(ESGICH)共识文件,采用计算机检索MEDLINE(MeSH词涉及每种药物或治疗家族)的综述。
主要发现
- 接受CD22靶向药(奥加伊妥珠单抗)患者的感染风险和谱与抗CD20抗体相似。
- CD33靶向药(吉妥珠单抗奥唑米星)所致风险因数据稀缺无法评估。
- 接受CD38靶向药(达雷妥尤单抗)患者面临水痘-带状疱疹病毒感染风险增加。
- CD40靶向药(卢卡妥木单抗或达西妥木单抗)治疗与类似高IgM综合征的机会性感染相关。
- SLAMF-7(CD319)靶向药(埃罗妥珠单抗)诱导淋巴细胞减少并增加感染风险(尤其VZV)。
关键数值与推荐
- CD30靶向药(维布妥昔单抗)推荐抗肺孢子菌预防和CMV感染监测。
- CD40靶向药需预防策略(包括抗肺孢子菌预防和CMV感染抢先治疗)。
- CCR4靶向药(莫格利珠单抗)推荐抗肺孢子菌和抗疱疹病毒预防及慢性HBV感染筛查。
临床怎么用
- 原文未据此给出推荐。
局限性
- CD33靶向药(吉妥珠单抗奥唑米星)所致风险因数据稀缺无法评估。
- CCR4靶向药(莫格利珠单抗)对感染易感性的影响难以与基础疾病和合并治疗的作用区分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4 and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: The risk and spectrum of infections in patients receiving CD22-targeted agents (i.e. inotuzumab ozogamicin) are similar to those observed with anti-CD20 antibodies. Anti-Pneumocystis prophylaxis and monitoring for cytomegalovirus (CMV) infection is recommended for patients receiving CD30-targeted agents (brentuximab vedotin). Due to the scarcity of data, the risk posed by CD33-targeted agents (gemtuzumab ozogamicin) cannot be assessed. Patients receiving CD38-targeted agents (i.e. daratumumab) face an increased risk of varicella-zoster virus (VZV) infection. Therapy with CD40-targeted agents (lucatumumab or dacetuzumab) is associated with opportunistic infections similar to those observed in hyper-IgM syndrome, and prevention strategies (including anti-Pneumocystis prophylaxis and pre-emptive therapy for CMV infection) are warranted. SLAMF-7 (CD319)-targeted agents (elotuzumab) induce lymphopenia and increase the risk of infection (particularly due to VZV). The impact of CCR4-targeted agents (mogamulizumab) on infection susceptibility is difficult to distinguish from the effect of underlying diseases and concomitant therapies. However, anti-Pneumocystis and anti-herpesvirus prophylaxis and screening for chronic hepatitis B virus (HBV) infection are recommended. IMPLICATIONS: Specific management strategies should be put in place to reduce the risk and/or the severity of infectious complications associated to the reviewed agents.
引用
- Drgona L, Gudiol C, Lanini S, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018. PMID: 29572070. doi:10.1016/j.cmi.2018.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。